Active Ingredient History
Baricitinib (trade name Olumiant) is an investigational drug for rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly. Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays. In February 2017 Baricitinib was approved for use in the European Union as a second-line therapy for moderate to severe active rheumatoid arthritis in adults, either alone or in combination with methotrexate. On 31 May 2018 FDA approved Barictinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Rheumatoid (approved 2010)
Alopecia (Phase 3)
Alopecia Areata (Phase 3)
Alzheimer Disease (Phase 1/Phase 2)
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Anhedonia (Phase 2)
Arthritis, Juvenile (Phase 3)
Arthritis, Rheumatoid (Phase 4)
Axial Spondyloarthritis (Phase 2)
Bone Density (Phase 3)
Brain Injuries, Traumatic (Phase 2)
Cognitive Dysfunction (Phase 1/Phase 2)
Communicable Diseases, Emerging (Phase 2/Phase 3)
Conjunctivitis (Phase 2)
Coronavirus Infections (Phase 3)
COVID-19 (Phase 4)
Depression (Phase 2)
Dermatitis, Allergic Contact (Early Phase 1)
Dermatitis, Atopic (Phase 3)
Dermatomyositis (Phase 3)
Diabetes Mellitus, Type 1 (Phase 2)
Diabetic Nephropathies (Phase 2)
Finger Joint (Phase 3)
Giant Cell Arteritis (Phase 2)
Gout (Phase 2/Phase 3)
Graft vs Host Disease (Phase 1/Phase 2)
Hair Diseases (Phase 3)
Healthcare-Associated Pneumonia (Phase 2/Phase 3)
Healthy Volunteers (Phase 1)
Hepatic Insufficiency (Phase 1)
Hereditary Autoinflammatory Diseases (Phase 2/Phase 3)
HIV (Phase 2)
Hypotrichosis (Phase 3)
Inflammation (Phase 1)
Inosine Triphosphate (Phase 2)
Lichen Planus (Phase 2)
Lichen Planus, Oral (Phase 2)
Lipodystrophy (Phase 2/Phase 3)
Livedoid Vasculopathy (Phase 2/Phase 3)
Liver Cirrhosis, Biliary (Phase 2)
Liver Diseases (Phase 1)
Lupus Erythematosus, Systemic (Phase 3)
Membranes (Phase 2)
Myalgia (Phase 2)
Myositis (Phase 2)
Nephritis (Phase 2/Phase 3)
Neuromyelitis Optica (Phase 1/Phase 2)
Pathological Conditions, Anatomical (Phase 3)
Pharmacology (Phase 3)
Pneumonia (Phase 2/Phase 3)
Pneumonia, Viral (Phase 3)
Psoriasis (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Pyoderma (Phase 2)
Pyoderma Gangrenosum (Phase 2)
Renal Insufficiency, Chronic (Phase 2)
Scleroderma, Systemic (Phase 4)
Sjogren's Syndrome (Phase 2)
Skin Diseases (Phase 3)
Skin Diseases, Papulosquamous (Phase 2)
Skin Ulcer (Phase 2)
Uveitis (Phase 3)
Vitiligo (Phase 2)
Wound Healing (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
